Trial · Interventional
Active, not recruitingPhase 4Registry dataInvestigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
Short name GAINPCCONTROL
Overview
- Status
- Active, not recruiting
- Phase
- Phase 4
- Enrollment
- 20 participants (estimated)
- Sponsor
- Hamilton Health Sciences Corporation · Other
- Design
- Allocation not applicable · Open label (no masking)
- Countries
1 country
Canada
- Start
- 2 Jul 2025
- Primary completion
- 31 Oct 2027 (estimated)
- Completion
- 31 Oct 2027 (estimated)
- First posted
- 3 Apr 2025
- Last update posted
- 14 Sept 2026
- Conditions
- Prostate Cancer
Timeline
1 trial · 1 ongoing
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
- Ph 4
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
Interventions
- Semaglutide Pen InjectorDrug
Arms1
Experimental
Semaglutide
The semaglutide dose will be 0.25mg subcutaneously once weekly for weeks 1-4, then 0.5mg once weekly for weeks 5-8, then 1mg once weekly for weeks 9-12, then 1.7mg once weekly for weeks 13-16, and then 2.4mg for the remainder of the trial. Semaglutide dose may be decreased in the case of adverse events to the highest tolerated dose.
Primary outcomes11
Outcomes the sponsor listed as primary.
Number of Serious Adverse Events
Time frame · 12 months
Registry description
An event that leads to death; is life-threatening; results in hospitalization or its prolongation; disability or permanent damage; congenital anomaly or birth defect; or other medical event that is considered serious.
Number of Adverse Events leading to Drug Discontinuation
Time frame · 6 months
Registry description
Adverse Events leading to Drug Discontinuation
Measure of Weight
Time frame · 12 months
Registry description
Measure of Weight
Measure of Waist Circumference
Time frame · 12 months
Registry description
Measure of Waist Circumference
Measure of Blood Pressure
Time frame · 12 months
Registry description
Measure of Blood Pressure
Concentration of HbA1c
Time frame · 12 months
Registry description
Concentration of HbA1c
Concentration of Lipids
Time frame · 12 months
Registry description
Total Cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides
Concentration of PSA
Time frame · 12 months
Registry description
Concentration of PSA
Concentration of Creatinine
Time frame · 12 months
Registry description
Concentration of Creatinine
Calculation of estimated glomerular rate
Time frame · 12 months
Registry description
Calculation of estimated glomerular rate
Number of Clinical Outcomes
Time frame · 12 months
Registry description
Death, Hospitalization, New Diabetes, Myocardial Infarction, Stroke, Heart Failure, Peripheral Arterial Disease, Venous Thromboembolism
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
A trial that is still running, or that stopped early, may post results later.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- Male
- Age
- from 18 Years
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
PepBank is a research reference. Talk to a doctor before you use any peptide.